Skip to main content

Table 2 Cytotoxicity and antiviral activity of CHLA and PUG against different virus infections a

From: Broad-spectrum antiviral activity of chebulagic acid and punicalagin against viruses that use glycosaminoglycans for entry

Virus Cell type Compounds CC50(μM)b Antiviral effect
     EC50(μM)c SId
HCMV HEL CHLA 306.32 ± 7.00 25.50 ± 1.51 12.01
   PUG 299.32 ± 9.14 16.76 ± 0.88 17.86
HCV Huh-7.5 CHLA 237.61 ± 4.53 12.16 ± 2.56 19.54
   PUG 222.61 ± 3.41 16.72 ± 2.55 13.31
DENV-2 Vero CHLA 159.63 ± 7.46 13.11 ± 0.72 12.18
   PUG 151.44 ± 9.31 7.86 ± 0.40 19.27
MV CHO-SLAM CHLA 351.83 ± 4.54 34.42 ± 4.35 10.22
   PUG 283.76 ± 11.54 25.49 ± 2.94 11.13
RSV HEp-2 CHLA 244.17 ± 17.40 0.38 ± 0.05 642.55
   PUG 264.83 ± 23.72 0.54 ± 0.04 490.43
VSV A549 CHLA 316.87 ± 9.01 61.28 ± 5.50 5.17
   PUG 318.84 ± 4.99 36.98 ± 4.59 8.62
ADV-5 A549 CHLA 316.87 ± 9.01 198.14 ± 14.07 1.60
   PUG 318.84 ± 4.99 196.67 ± 20.05 1.62
  1. a Values shown are means obtained from three independent experiments with each treatment performed in triplicate.
  2. b Cytotoxic effects were evaluated by XTT assay to determine the concentration of 50% cellular cytotoxicity (CC50) of the tested compounds.
  3. c Antiviral effects were evaluated by infection analysis to determine the effective concentration that achieved 50% inhibition (EC50) against the specific virus examined.
  4. d SI, selectivity index. SI = CC50/EC50.